P2X7 Receptor in Hematological Malignancies

Marchi, Elena De; Pegoraro, Anna; Adinolfi, Elena

doi:10.3389/fcell.2021.645605

Cited by 15 publications

(14 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Malignant hematopoietic stem cells have also been shown to overexpress P2X7 receptors, if compared to their non-pathological counterpart [ 77 , 78 ]. In particular, acute myeloid leukemia (AML)-associated leukemic initiating cells (LICs) formed, proliferated, renewed and homed at the endosteal niche in a P2X7 receptor dependent fashion [ 79 ].…”

Section: P2x7 Receptor Relevance In Metabolismmentioning

confidence: 99%

Cancer Metabostemness and Metabolic Reprogramming via P2X7 Receptor

Rabelo

Arnaud-Sampaio

Adinolfi

et al. 2021

Cells

Self Cite

View full text Add to dashboard Cite

The heterogeneity of tumor cell mass and the plasticity of cancer cell phenotypes in solid tumors allow for the insurgence of resistant and metastatic cells, responsible for cancer patients’ clinical management’s main challenges. Among several factors that are responsible for increased cancer aggression, metabolic reprogramming is recently emerging as an ultimate cancer hallmark, as it is central for cancer cell survival and self-renewal, metastasis and chemoresistance. The P2X7 receptor, whose expression is upregulated in many solid and hematological malignancies, is also emerging as a good candidate in cancer metabolic reprogramming and the regulation of stem cell proliferation and differentiation. Metabostemness refers to the metabolic reprogramming of cancer cells toward less differentiated (CSCs) cellular states, and we believe that there is a strong correlation between metabostemness and P2X7 receptor functions in oncogenic processes. Here, we summarize important aspects of P2X7 receptor functions in normal and tumor tissues as well as essential aspects of its structure, regulation, pharmacology and its clinical use. Finally, we review current knowledge implicating P2X7 receptor functions in cancer-related molecular pathways, in metabolic reprogramming and in metabostemness.

show abstract

Section: P2x7 Receptor Relevance In Metabolismmentioning

confidence: 99%

Cancer Metabostemness and Metabolic Reprogramming via P2X7 Receptor

Rabelo

Arnaud-Sampaio

Adinolfi

et al. 2021

Cells

Self Cite

View full text Add to dashboard Cite

show abstract

“…To the best of our knowledge there are no reports examining human donor and recipient ENTPD1 (CD39), NT5E (CD73) and ADORA2A (A 2A ) genotypes and allo-HSCT outcomes in the clinical setting. Finally, it should be noted that purinergic receptors and molecules play emerging roles in blood cancer cells [ 79 , 80 ], but this is beyond the scope of this review.…”

Section: Purinergic Signalling In Allogeneic Haematopoietic Stem Cell Transplantationmentioning

confidence: 99%

Purinergic Signalling in Allogeneic Haematopoietic Stem Cell Transplantation and Graft-versus-Host Disease

Cuthbertson

Geraghty

Adhikary

et al. 2021

IJMS

View full text Add to dashboard Cite

Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is a curative therapy for blood cancers and other haematological disorders. However, allo-HSCT leads to graft-versus-host disease (GVHD), a severe and often lethal immunological response, in the majority of transplant recipients. Current therapies for GVHD are limited and often reduce the effectiveness of allo-HSCT. Therefore, pro- and anti-inflammatory factors contributing to disease need to be explored in order to identify new treatment targets. Purinergic signalling plays important roles in haematopoiesis, inflammation and immunity, and recent evidence suggests that it can also affect haematopoietic stem cell transplantation and GVHD development. This review provides a detailed assessment of the emerging roles of purinergic receptors, most notably P2X7, P2Y2 and A2A receptors, and ectoenzymes, CD39 and CD73, in GVHD.

show abstract

“…However, a recent meta-analysis studying the link between rs3751143 and cancer risk minored these results [93]. Nevertheless, in the field of hematological malignancies, P2RX7 and its genetic variants are now considered as biomarkers and potential therapeutic tools [94].…”

Section: P2rx7 and Genomic Instabilitymentioning

confidence: 99%

To inhibit or to boost the ATP/P2RX7 pathway to fight cancer—that is the question

Hreich

Benzaquen

Hofman

et al. 2021

Purinergic Signalling

View full text Add to dashboard Cite

Despite new biological insights and recent therapeutic advances, many tumors remain at baseline during treatments. Therefore, there is an urgent need to find new therapeutic strategies to improve the care of patients with solid tumors. P2RX7 receptor (P2XR7), an ATPgated ion channel characterized by its ability to form large pore within the cell membrane, is described by most of the investigators as a "chef d'orchestre" of the antitumor immune response. The purpose of this review is to detail the recent information concerning different cellular mechanisms linking P2RX7 to hallmarks of cancer and to discuss different progresses in elucidating how activation of the ATP/P2RX7/NLRP3/IL-18 pathway is a very promising approach to fight cancer progression by increasing antitumor immune responses.

show abstract

P2X7 Receptor in Hematological Malignancies

Cited by 15 publications

References 74 publications

Cancer Metabostemness and Metabolic Reprogramming via P2X7 Receptor

Cancer Metabostemness and Metabolic Reprogramming via P2X7 Receptor

Purinergic Signalling in Allogeneic Haematopoietic Stem Cell Transplantation and Graft-versus-Host Disease

To inhibit or to boost the ATP/P2RX7 pathway to fight cancer—that is the question

Contact Info

Product

Resources

About